An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517525-10-00

Acronym

MZE829-201

Enrollment

Registered

2025-06-25

Start date

2025-09-15

Completion date

Unknown

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

APOL1 Kidney Disease (AKD)

Brief summary

Safety and tolerability based on incidence of adverse events (AEs), and changes in vital signs, clinical laboratory assessments, 12-lead electrocardiograms (ECGs)

Interventions

DRUGMZE829

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety and tolerability based on incidence of adverse events (AEs), and changes in vital signs, clinical laboratory assessments, 12-lead electrocardiograms (ECGs)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026